Asthma

40% of asthma patients overusing inhalers, says data 

5 April 2022

New results from an observational data analysis of asthma inhaler therapy found that short-acting beta2-agonist (SABA) reliever overuse is a global issue adversely impacting asthma outcomes.1,2   Data from across the SABA Use IN Asthma (SABINA) global programme have been published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice) and the […]

New data reinforce efficacy of asthma drug 

15 March 2022

Results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase III and PATHWAY Phase IIb trials showed AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated reductions in the annualised asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.1 According to the company, these findings support the role of Tezspire as a first-in-class treatment […]